CNS Trial Failure Rates High As Need For New Drugs Grows
Source: WCG
We need to improve the conduct of CNS trials. The failure rate of CNS drugs in phase 2 and 3 clinical trials is around 85%, second only to Oncology. Because of this failure rate, many large pharmaceutical companies are exiting the space. At the same time, the need for CNS therapies has never been more acute, and there is a pressing need for both disease modifying and symptomatic treatments.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more